GTx-758

From WikiMD's Medical Encyclopedia

(Redirected from Capesaris)

GTX-758_structure.png

GTx-758 is an investigational drug developed for the treatment of prostate cancer. It is a nonsteroidal selective estrogen receptor alpha agonist (SERAA) that works by reducing the levels of testosterone in the body, which is a key driver of prostate cancer growth.

Mechanism of Action[edit]

GTx-758 functions by selectively activating the estrogen receptor alpha (ERα) in the pituitary gland and hypothalamus. This activation leads to a decrease in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn reduces the production of testosterone by the testes. Lower testosterone levels can help slow the progression of prostate cancer.

Clinical Development[edit]

GTx-758 has undergone several clinical trials to evaluate its safety and efficacy in patients with prostate cancer. These trials have shown that GTx-758 can effectively lower testosterone levels without the need for androgen deprivation therapy (ADT), which is commonly associated with significant side effects such as hot flashes, osteoporosis, and loss of libido.

Potential Benefits[edit]

The use of GTx-758 offers several potential benefits over traditional ADT. By selectively targeting ERα, GTx-758 may reduce the risk of side effects commonly associated with ADT. Additionally, GTx-758 has been shown to maintain bone density and improve quality of life in patients undergoing treatment for prostate cancer.

Side Effects[edit]

As with any medication, GTx-758 may cause side effects. Common side effects observed in clinical trials include gynecomastia, nausea, and fatigue. However, these side effects are generally considered to be less severe than those associated with traditional ADT.

Current Status[edit]

As of the latest updates, GTx-758 is still under investigation and has not yet received approval from regulatory authorities such as the Food and Drug Administration (FDA) for general use in the treatment of prostate cancer. Ongoing research aims to further establish its safety profile and therapeutic efficacy.

See Also[edit]

References[edit]

External Links[edit]

-


Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.